Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41589-022-01094-4 http://scihub22266oqcxt.onion/10.1038/s41589-022-01094-4 35879545!10082993!35879545     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\35879545.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Nat+Chem+Biol 2022 ; 18 (10): 1056-1064 Nephropedia Template TP {{tp|p=35879545|t=2022. Cas13d knockdown of lung protease Ctsl prevents and treats SARS-CoV-2 infection |pdf=|usr=}}{{35879545}} gab.com Text Cas13d knockdown of lung protease Ctsl prevents and treats SARS-CoV-2 infection JO: Nat Chem Biol http://www.kidney.de/pget.php?&tw=1&pmid=35879545 #FOAvip SARS-CoV-2 entry into cells requires specific host proteases; however, no successful in vivo applications of host protease inhibitors have yet been reported for treatment of SARS-CoV-2 pathogenesis. Here we describe a chemically engineered nanosystem encapsulating CRISPR-Cas13d, developed to specifically target lung protease cathepsin L (Ctsl) messenger RNA to block SARS-CoV-2 infection in mice. We show that this nanosystem decreases lung Ctsl expression in normal mice efficiently, specifically and safely. We further show that this approach extends survival of mice lethally infected with SARS-CoV-2, correlating with decreased lung virus burden, reduced expression of proinflammatory cytokines/chemokines and diminished severity of pulmonary interstitial inflammation. Postinfection treatment by this nanosystem dramatically lowers the lung virus burden and alleviates virus-induced pathological changes. Our results indicate that targeting lung protease mRNA by Cas13d nanosystem represents a unique strategy for controlling SARS-CoV-2 infection and demonstrate that CRISPR can be used as a potential treatment for SARS-CoV-2 infection. Twit Text FOAVip Cas13d knockdown of lung protease Ctsl prevents and treats SARS-CoV-2 infection ????Nat Chem Biol http://www.kidney.de/pget.php?&tw=1&pmid=35879545 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=35879545 #FOAvip English Wikipedia <ref>{{Cite pmid|35879545}}</ref> Cas13d knockdown of lung protease Ctsl prevents and treats SARS-CoV-2 infection #MMPMID35879545 Cui Z; Zeng C; Huang F; Yuan F; Yan J; Zhao Y; Zhou Y; Hankey W; Jin VX; Huang J; Staats HF; Everitt JI; Sempowski GD; Wang H; Dong Y; Liu SL; Wang Q Nat Chem Biol 2022[Oct]; 18 (10): 1056-1064 PMID35879545show ga SARS-CoV-2 entry into cells requires specific host proteases; however, no successful in vivo applications of host protease inhibitors have yet been reported for treatment of SARS-CoV-2 pathogenesis. Here we describe a chemically engineered nanosystem encapsulating CRISPR-Cas13d, developed to specifically target lung protease cathepsin L (Ctsl) messenger RNA to block SARS-CoV-2 infection in mice. We show that this nanosystem decreases lung Ctsl expression in normal mice efficiently, specifically and safely. We further show that this approach extends survival of mice lethally infected with SARS-CoV-2, correlating with decreased lung virus burden, reduced expression of proinflammatory cytokines/chemokines and diminished severity of pulmonary interstitial inflammation. Postinfection treatment by this nanosystem dramatically lowers the lung virus burden and alleviates virus-induced pathological changes. Our results indicate that targeting lung protease mRNA by Cas13d nanosystem represents a unique strategy for controlling SARS-CoV-2 infection and demonstrate that CRISPR can be used as a potential treatment for SARS-CoV-2 infection. |*COVID-19 Drug Treatment[MESH] |Animals[MESH] |Cathepsin L[MESH] |Chemokines[MESH] |Cytokines[MESH] |Endopeptidases[MESH] |Lung/pathology[MESH] |Mice[MESH] |Peptide Hydrolases[MESH] |Protease Inhibitors/pharmacology[MESH] |RNA, Messenger/genetics[MESH]Cas13d knockdown of lung protease Ctsl prevents and treats SARS-CoV-2 (epmc).pdf DeepDyve Pubget Overpricing